Lupin Signs Exclusive Licensing Deal With Valorum for Biosimilar Armlupeg™ in the U.S.

Lupin Limited has entered into an **exclusive licensing agreement** with U.S.-based biosimilar specialist **Valorum Biologics** for its pegfilgrastim biosimilar **Armlupeg™ (pegfilgrastim-unne)**. Under the arrangement, Valorum will handle **commercialization and distribution** in the United States, while Lupin will continue to **manufacture and supply** the product. The company will receive an **upfront license fee along with royalties** on net sales. Lupin’s U.S. Generics President **Spiro Gavaris** said the partnership strengthens Lupin’s footprint in the U.S. biosimilar market and supports wider access to affordable oncology supportive-care treatments. Valorum CEO **Par S. Hyare** added that the company aims to capture meaningful market share through its specialty-commercial expertise. Armlupeg™ is indicated for reducing the **duration of neutropenia and the incidence of febrile neutropenia** in chemotherapy patients. --- ### **Disclaimer** This article is for informational purposes only and not investment advice. Always consult a financial advisor before making investment decisions. **Follow for more sharp & reliable financial updates.**